Argen X Aktie - ARGX

Argen X SE (ARGX) Aktie

Professionelle Tools für Privatanleger.

Premium

Current Price

784,40

( 0,33% )

Gebot

776,40

Fragen

796,00

Volumen

77.060

774,00 Tagesbereich 794,80

456,60 52-Wochen-Bereich 813,60

Handelsende

781,80

Handelsbeginn

784,20

Letzte Trade

784.4

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

93.038

Finanzvolumen

VWAP

argenx to Host Autoimmune Myositis R&D Webinar

June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global...

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and...

argenx to Host Myositis R&D Webinar on June 23, 2026

May 28, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx to Present at Upcoming Investor Conferences

May 27, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients...

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

$1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti-AChR...

argenx to Present at BofA Securities 2026 Health Care Conference

May 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE...

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

April 30, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	5	0.64151911727	779.4	813.6	743.2	133635	779.70991207	DE
4	66.2	9.21748816486	718.2	813.6	674.8	118072	751.22820711	DE
12	140.6	21.8390804598	643.8	813.6	634.6	93038	715.13447668	DE
26	89.6	12.8957973518	694.8	813.6	568.4	96377	681.8665053	DE
52	303.2	63.0091438071	481.2	813.6	456.6	95139	664.56745527	DE
156	421.4	116.08815427	363	813.6	271	74386	541.87476798	DE
260	518.8	195.331325301	265.6	813.6	224.1	70827	455.91919153	DE

ARGX - Frequently Asked Questions (FAQ)

What is the current Argen X SE share price?

The current share price of Argen X SE is 784,40 €

What is the 1 year trading range for Argen X SE share price?

Argen X SE has traded in the range of 456,60 € to 813,60 € during the past year

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Argen X SE (ARGX)

Argen X SE (ARGX) Aktie

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

ARGX Neueste Nachrichten

argenx to Host Autoimmune Myositis R&D Webinar

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

argenx to Host Myositis R&D Webinar on June 23, 2026

argenx to Present at Upcoming Investor Conferences

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

argenx to Present at BofA Securities 2026 Health Care Conference

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

argenx to Host Autoimmune Myositis R&D Webinar

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

argenx to Host Myositis R&D Webinar on June 23, 2026

argenx to Present at Upcoming Investor Conferences

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

argenx to Present at BofA Securities 2026 Health Care Conference

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

argenx announces Annual General Meeting of Shareholders on May 6, 2026

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

ARGX - Frequently Asked Questions (FAQ)

ARGX Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen